• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bone Biologics Corp - Common Stock (NQ:BBLG)

    0.9194 -0.0606 (-6.18%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Bone Biologics Corp - Common Stock

    < Previous 1 2 Next >
    News headline image
    Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
    Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash 
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
    Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up 
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
    Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance 
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
    Milestone advances manufacturing readiness and supports long-term commercialization strategy 
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces Closing of $5.0 Million Public Offering
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Peraso (NASDAQ: PRSO) Pushes Back on Mobix Labs (NASDAQ: MOBX) Takeover Bid, Valuation, Nasdaq Compliance Etc. – More Stocks Inside
    Via AB Newswire
    Topics Regulatory Compliance
    News headline image
    Bone Biologics Announces Pricing of $5.0 Million Public Offering
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Files Patent Application for Bone Regeneration Technology
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces 1-for-6 Reverse Stock Split
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
    From Bone Biologics
    Via Business Wire
    News headline image
    Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Life Sciences Virtual Investor Forum Agenda Announced for June 20th
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Bone Biologics Announces Closing of $2.0 Million Public Offering
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces Pricing of $2.0 Million Public Offering
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Reports Progress With NB1 Clinical Program
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces 1-for-8 Reverse Stock Split
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
    From Bone Biologics
    Via Business Wire
    BioMedNewsBreaks – Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public Offering
    Via Investor Brand Network
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.